The principles of PK-tailored prophylaxis

Hamostaseologie

Volumn 33, Issue SUPPL.1, 2013, Pages

  Chehadeh, H E ^a   Reininger, A J ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

ABR; Annual bleed rate; FVIII trough level; Haemophilia A; Individualized treatment; PK tailored prophylaxis; Target joint

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; HEMOPHILIA A; HUMAN; PAIN; PROPHYLAXIS; QUALITY OF LIFE; QUESTIONNAIRE; SINGLE DRUG DOSE; TREATMENT DURATION;

ABR; ANNUAL BLEED RATE; FVIII TROUGH LEVEL; HAEMOPHILIA A; INDIVIDUALIZED TREATMENT; PK TAILORED PROPHYLAXIS; TARGET JOINT;

BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84888392703     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619800     Document Type: Article

References (20)

1. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
2. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
3. Collins P, Fischer K, Blanchette V et al. Effect of normal variation in FVIII pharmacokinetics on prophylactic dosing requirements in severe hemophilia. Blood 2008; 112: 445.
4. Collins PW, Blanchette VS, Fischer K et al. Breakthrough bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009; 7: 413-420.
5. Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. London: European Agency for the Evaluation of Medicinal Products (EMEA) 2009. Report No. EMEA/CHMP/BPWP/144533/2009.
6. Den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. Blood Transfus. In press 2012.
7. Den Uijl IEM, Mauser Bunchoten EP, Roosendaal G et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-853.
8. Funk M, Schmidt H, Escuriola-ettingshausen C et al. Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis. Ann Hematol 1998; 77: 171-174.
9. Funk MB, Schmidt H, Becker S et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002; 8: 98-103.
10. Lindvall K, Astermark J, Björkman S et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855-859.
11. Lundin B, Ljung R, Pettersson H, The European Paediatric Network for Haemophilia Management (PEDNET). MRI scores of ankle joints in children with haemophilia - comparison with clinical data. Haemophilia 2005; 11: 116-122.
12. Manco-johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
13. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
14. Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.
15. Rodriguez-merchan EC. Musculoskeletal Complications of Hemophilia. HSS J 2010; 6: 37-42.
16. Santagostino E, Mancuso ME. Prevention of arthropathy in haemophilia: prophylaxis. Haemophilia 2008; 14: 16-19.
17. Stephensen D, Tait RC, Brodie N et al. Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia 2009; 15: 1210-1214.
18. Tuddenham E. Gene therapy for haemophilia B. Haemophilia 2012; 18 (Suppl 4): 13-17.
19. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-367.
20. Van Dijk K, Fischer K, Van Der Bom JG et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 438-443.